Is Amazon an AI Stock?
With the market starting to look skittish on pure-play AI…
Sell
31
NRXP Quote, Financials, Valuation and Earnings
Last price:
$2.43
Seasonality move
:
51.98%
Day range:
$2.36 - $2.51
52-week range:
$1.15 - $6.01
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
170.09x
P/B ratio:
--
Volume:
338.5K
Avg. volume:
460.7K
1-year change:
91.27%
Market cap:
$67.7M
Revenue:
--
EPS (TTM):
-$2.35
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
NRXP
NRX Pharmaceuticals, Inc.
|
$6.1M | -$0.02 | -- | -92.24% | $36.50 |
|
ACXP
Acurx Pharmaceuticals, Inc.
|
-- | -$1.49 | -- | -69.54% | $61.70 |
|
AIM
AIM ImmunoTech
|
-- | -$0.09 | -23.08% | -53.85% | $4.50 |
|
CVM
CEL-SCI Corp.
|
-- | -- | -- | -- | $42.50 |
|
IGC
IGC Pharma, Inc.
|
$383K | -$0.02 | -7.04% | -11.5% | $3.75 |
|
SNYR
Synergy CHC
|
-- | -- | -- | -- | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
NRXP
NRX Pharmaceuticals, Inc.
|
$2.41 | $36.50 | $67.7M | -- | $0.00 | 0% | 170.09x |
|
ACXP
Acurx Pharmaceuticals, Inc.
|
$3.48 | $61.70 | $5.4M | -- | $0.00 | 0% | -- |
|
AIM
AIM ImmunoTech
|
$0.04 | $4.50 | $2.8M | -- | $0.00 | 0% | 13.27x |
|
CVM
CEL-SCI Corp.
|
$5.96 | $42.50 | $18.1M | -- | $0.00 | 0% | -- |
|
IGC
IGC Pharma, Inc.
|
$0.30 | $3.75 | $28M | -- | $0.00 | 0% | 22.66x |
|
SNYR
Synergy CHC
|
-- | -- | -- | -- | $0.00 | 0% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
NRXP
NRX Pharmaceuticals, Inc.
|
-67.82% | 1.940 | 11.39% | 0.19x |
|
ACXP
Acurx Pharmaceuticals, Inc.
|
-- | 3.600 | -- | 2.39x |
|
AIM
AIM ImmunoTech
|
48.41% | 0.745 | 17.25% | 0.71x |
|
CVM
CEL-SCI Corp.
|
58.65% | 1.679 | 143.38% | 0.32x |
|
IGC
IGC Pharma, Inc.
|
1.82% | 0.805 | 0.39% | 0.78x |
|
SNYR
Synergy CHC
|
-- | 0.000 | -- | -- |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
NRXP
NRX Pharmaceuticals, Inc.
|
$104K | -$4.1M | -- | -- | -1701.65% | -$2.9M |
|
ACXP
Acurx Pharmaceuticals, Inc.
|
-- | -$2M | -358.38% | -358.38% | -- | -$1.9M |
|
AIM
AIM ImmunoTech
|
$27K | -$4.5M | -219.06% | -256.33% | -9994.29% | -$3.3M |
|
CVM
CEL-SCI Corp.
|
-$959K | -$5.5M | -123.39% | -266.61% | -- | -$3.9M |
|
IGC
IGC Pharma, Inc.
|
-$6K | -$2.9M | -91.27% | -94.42% | -1517.8% | -$2.4M |
|
SNYR
Synergy CHC
|
-- | -- | -- | -- | -- | -- |
NRX Pharmaceuticals, Inc. vs. Competitors
-
Which has Higher Returns NRXP or ACXP?
Acurx Pharmaceuticals, Inc. has a net margin of -2433.88% compared to NRX Pharmaceuticals, Inc.'s net margin of --. NRX Pharmaceuticals, Inc.'s return on equity of -- beat Acurx Pharmaceuticals, Inc.'s return on equity of -358.38%.
Company Gross Margin Earnings Per Share Invested Capital NRXPNRX Pharmaceuticals, Inc.42.98% -$0.26 -$15.3M ACXPAcurx Pharmaceuticals, Inc.-- -$1.23 $3.6M -
What do Analysts Say About NRXP or ACXP?
NRX Pharmaceuticals, Inc. has a consensus price target of $36.50, signalling upside risk potential of 1414.52%. On the other hand Acurx Pharmaceuticals, Inc. has an analysts' consensus of $61.70 which suggests that it could grow by 1672.99%. Given that Acurx Pharmaceuticals, Inc. has higher upside potential than NRX Pharmaceuticals, Inc., analysts believe Acurx Pharmaceuticals, Inc. is more attractive than NRX Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings NRXPNRX Pharmaceuticals, Inc.4 0 0 ACXPAcurx Pharmaceuticals, Inc.1 0 0 -
Is NRXP or ACXP More Risky?
NRX Pharmaceuticals, Inc. has a beta of 1.914, which suggesting that the stock is 91.412% more volatile than S&P 500. In comparison Acurx Pharmaceuticals, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock NRXP or ACXP?
NRX Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Acurx Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. NRX Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Acurx Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios NRXP or ACXP?
NRX Pharmaceuticals, Inc. quarterly revenues are $242K, which are larger than Acurx Pharmaceuticals, Inc. quarterly revenues of --. NRX Pharmaceuticals, Inc.'s net income of -$5.9M is lower than Acurx Pharmaceuticals, Inc.'s net income of -$2M. Notably, NRX Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Acurx Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for NRX Pharmaceuticals, Inc. is 170.09x versus -- for Acurx Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income NRXPNRX Pharmaceuticals, Inc.170.09x -- $242K -$5.9M ACXPAcurx Pharmaceuticals, Inc.-- -- -- -$2M
-
Which has Higher Returns NRXP or AIM?
AIM ImmunoTech has a net margin of -2433.88% compared to NRX Pharmaceuticals, Inc.'s net margin of -10571.43%. NRX Pharmaceuticals, Inc.'s return on equity of -- beat AIM ImmunoTech's return on equity of -256.33%.
Company Gross Margin Earnings Per Share Invested Capital NRXPNRX Pharmaceuticals, Inc.42.98% -$0.26 -$15.3M AIMAIM ImmunoTech77.14% -$0.06 $5.6M -
What do Analysts Say About NRXP or AIM?
NRX Pharmaceuticals, Inc. has a consensus price target of $36.50, signalling upside risk potential of 1414.52%. On the other hand AIM ImmunoTech has an analysts' consensus of $4.50 which suggests that it could grow by 11066.25%. Given that AIM ImmunoTech has higher upside potential than NRX Pharmaceuticals, Inc., analysts believe AIM ImmunoTech is more attractive than NRX Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings NRXPNRX Pharmaceuticals, Inc.4 0 0 AIMAIM ImmunoTech1 0 0 -
Is NRXP or AIM More Risky?
NRX Pharmaceuticals, Inc. has a beta of 1.914, which suggesting that the stock is 91.412% more volatile than S&P 500. In comparison AIM ImmunoTech has a beta of 0.760, suggesting its less volatile than the S&P 500 by 23.953%.
-
Which is a Better Dividend Stock NRXP or AIM?
NRX Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. AIM ImmunoTech offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. NRX Pharmaceuticals, Inc. pays -- of its earnings as a dividend. AIM ImmunoTech pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios NRXP or AIM?
NRX Pharmaceuticals, Inc. quarterly revenues are $242K, which are larger than AIM ImmunoTech quarterly revenues of $35K. NRX Pharmaceuticals, Inc.'s net income of -$5.9M is lower than AIM ImmunoTech's net income of -$3.7M. Notably, NRX Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while AIM ImmunoTech's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for NRX Pharmaceuticals, Inc. is 170.09x versus 13.27x for AIM ImmunoTech. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income NRXPNRX Pharmaceuticals, Inc.170.09x -- $242K -$5.9M AIMAIM ImmunoTech13.27x -- $35K -$3.7M
-
Which has Higher Returns NRXP or CVM?
CEL-SCI Corp. has a net margin of -2433.88% compared to NRX Pharmaceuticals, Inc.'s net margin of --. NRX Pharmaceuticals, Inc.'s return on equity of -- beat CEL-SCI Corp.'s return on equity of -266.61%.
Company Gross Margin Earnings Per Share Invested Capital NRXPNRX Pharmaceuticals, Inc.42.98% -$0.26 -$15.3M CVMCEL-SCI Corp.-- -$1.36 $17M -
What do Analysts Say About NRXP or CVM?
NRX Pharmaceuticals, Inc. has a consensus price target of $36.50, signalling upside risk potential of 1414.52%. On the other hand CEL-SCI Corp. has an analysts' consensus of $42.50 which suggests that it could grow by 613.09%. Given that NRX Pharmaceuticals, Inc. has higher upside potential than CEL-SCI Corp., analysts believe NRX Pharmaceuticals, Inc. is more attractive than CEL-SCI Corp..
Company Buy Ratings Hold Ratings Sell Ratings NRXPNRX Pharmaceuticals, Inc.4 0 0 CVMCEL-SCI Corp.1 0 0 -
Is NRXP or CVM More Risky?
NRX Pharmaceuticals, Inc. has a beta of 1.914, which suggesting that the stock is 91.412% more volatile than S&P 500. In comparison CEL-SCI Corp. has a beta of 0.487, suggesting its less volatile than the S&P 500 by 51.259%.
-
Which is a Better Dividend Stock NRXP or CVM?
NRX Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CEL-SCI Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. NRX Pharmaceuticals, Inc. pays -- of its earnings as a dividend. CEL-SCI Corp. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios NRXP or CVM?
NRX Pharmaceuticals, Inc. quarterly revenues are $242K, which are larger than CEL-SCI Corp. quarterly revenues of --. NRX Pharmaceuticals, Inc.'s net income of -$5.9M is lower than CEL-SCI Corp.'s net income of -$5.7M. Notably, NRX Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while CEL-SCI Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for NRX Pharmaceuticals, Inc. is 170.09x versus -- for CEL-SCI Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income NRXPNRX Pharmaceuticals, Inc.170.09x -- $242K -$5.9M CVMCEL-SCI Corp.-- -- -- -$5.7M
-
Which has Higher Returns NRXP or IGC?
IGC Pharma, Inc. has a net margin of -2433.88% compared to NRX Pharmaceuticals, Inc.'s net margin of -953.4%. NRX Pharmaceuticals, Inc.'s return on equity of -- beat IGC Pharma, Inc.'s return on equity of -94.42%.
Company Gross Margin Earnings Per Share Invested Capital NRXPNRX Pharmaceuticals, Inc.42.98% -$0.26 -$15.3M IGCIGC Pharma, Inc.-3.14% -$0.02 $8.2M -
What do Analysts Say About NRXP or IGC?
NRX Pharmaceuticals, Inc. has a consensus price target of $36.50, signalling upside risk potential of 1414.52%. On the other hand IGC Pharma, Inc. has an analysts' consensus of $3.75 which suggests that it could grow by 1141.72%. Given that NRX Pharmaceuticals, Inc. has higher upside potential than IGC Pharma, Inc., analysts believe NRX Pharmaceuticals, Inc. is more attractive than IGC Pharma, Inc..
Company Buy Ratings Hold Ratings Sell Ratings NRXPNRX Pharmaceuticals, Inc.4 0 0 IGCIGC Pharma, Inc.2 0 0 -
Is NRXP or IGC More Risky?
NRX Pharmaceuticals, Inc. has a beta of 1.914, which suggesting that the stock is 91.412% more volatile than S&P 500. In comparison IGC Pharma, Inc. has a beta of 0.242, suggesting its less volatile than the S&P 500 by 75.839%.
-
Which is a Better Dividend Stock NRXP or IGC?
NRX Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. IGC Pharma, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. NRX Pharmaceuticals, Inc. pays -- of its earnings as a dividend. IGC Pharma, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios NRXP or IGC?
NRX Pharmaceuticals, Inc. quarterly revenues are $242K, which are larger than IGC Pharma, Inc. quarterly revenues of $191K. NRX Pharmaceuticals, Inc.'s net income of -$5.9M is lower than IGC Pharma, Inc.'s net income of -$1.8M. Notably, NRX Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while IGC Pharma, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for NRX Pharmaceuticals, Inc. is 170.09x versus 22.66x for IGC Pharma, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income NRXPNRX Pharmaceuticals, Inc.170.09x -- $242K -$5.9M IGCIGC Pharma, Inc.22.66x -- $191K -$1.8M
-
Which has Higher Returns NRXP or SNYR?
Synergy CHC has a net margin of -2433.88% compared to NRX Pharmaceuticals, Inc.'s net margin of --. NRX Pharmaceuticals, Inc.'s return on equity of -- beat Synergy CHC's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital NRXPNRX Pharmaceuticals, Inc.42.98% -$0.26 -$15.3M SNYRSynergy CHC-- -- -- -
What do Analysts Say About NRXP or SNYR?
NRX Pharmaceuticals, Inc. has a consensus price target of $36.50, signalling upside risk potential of 1414.52%. On the other hand Synergy CHC has an analysts' consensus of -- which suggests that it could fall by --. Given that NRX Pharmaceuticals, Inc. has higher upside potential than Synergy CHC, analysts believe NRX Pharmaceuticals, Inc. is more attractive than Synergy CHC.
Company Buy Ratings Hold Ratings Sell Ratings NRXPNRX Pharmaceuticals, Inc.4 0 0 SNYRSynergy CHC0 0 0 -
Is NRXP or SNYR More Risky?
NRX Pharmaceuticals, Inc. has a beta of 1.914, which suggesting that the stock is 91.412% more volatile than S&P 500. In comparison Synergy CHC has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock NRXP or SNYR?
NRX Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Synergy CHC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. NRX Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Synergy CHC pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios NRXP or SNYR?
NRX Pharmaceuticals, Inc. quarterly revenues are $242K, which are larger than Synergy CHC quarterly revenues of --. NRX Pharmaceuticals, Inc.'s net income of -$5.9M is higher than Synergy CHC's net income of --. Notably, NRX Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Synergy CHC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for NRX Pharmaceuticals, Inc. is 170.09x versus -- for Synergy CHC. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income NRXPNRX Pharmaceuticals, Inc.170.09x -- $242K -$5.9M SNYRSynergy CHC-- -- -- --
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Google Vs NVIDIA Stock: Which Is Best?
Alphabet (NASDAQ:GOOGL) and NVIDIA (NASDAQ:NVIDIA) are two of the market’s…
How High Could NVIDIA Stock Go?
NVIDIA (NASDAQ:NVDA) has been one of the best stocks to…
Stock Ideas
Buy
51
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 61x
Buy
61
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 38x
Buy
69
Is GOOG Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 40x
Alerts
Sell
47
PSTG alert for Dec 4
Pure Storage, Inc. [PSTG] is up 5.05% over the past day.
Sell
41
SMX alert for Dec 4
SMX (Security Matters) Plc [SMX] is up 154.74% over the past day.
Sell
43
HY alert for Dec 5
Hyster-Yale, Inc. [HY] is up 1.92% over the past day.
